美国 - 英文 - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

alcon laboratories australia pty ltd (nz) - dextran 0.1%; disodium edetate dihydrate 0.1%; hypromellose 0.3%; sodium chloride 0.77% - contact lens solution - active: dextran 0.1% disodium edetate dihydrate 0.1% hypromellose 0.3% sodium chloride 0.77%

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

alcon laboratories australia pty ltd (nz) - boric acid 0.2%; disodium edetate dihydrate 0.1%; hyetellose 0.8%; sodium chloride 0.6% - contact lens solution - active: boric acid 0.2% disodium edetate dihydrate 0.1% hyetellose 0.8% sodium chloride 0.6%

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - baquacil 0.0286 mg/ml ((20% solution)); chlorhexidine gluconate 0.176 mg/ml (20% solution); disodium edetate dihydrate 0.5 mg/ml - contact lens solution - active: baquacil 0.0286 mg/ml ((20% solution)) chlorhexidine gluconate 0.176 mg/ml (20% solution) disodium edetate dihydrate 0.5 mg/ml excipient: dibasic sodium phosphate dimeticone hypromellose methyl gluceth-20 monobasic potassium phosphate polysorbate 20 potassium chloride purified water sodium chloride surfactants

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - boric acid; chlorhexidine gluconate; disodium edetate dihydrate; sodium chloride - contact lens solution - active: boric acid chlorhexidine gluconate disodium edetate dihydrate sodium chloride

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - lodoxamide trometamol 1.78 mg/ml equivalent to 1 mg/ml lodoxamide - eye drops, solution - 1 mg/ml - active: lodoxamide trometamol 1.78 mg/ml equivalent to 1 mg/ml lodoxamide excipient: benzalkonium chloride citric acid monohydrate disodium edetate dihydrate hydrochloric acid hypromellose mannitol purified water sodium citrate dihydrate sodium hydroxide tyloxapol - lomide eye drops 0.1% are indicated in the treatment of non-infectious allergic conjunctivitis (vernal conjunctivitis, giant papillary conjunctivitis and seasonal allergic conjunctivitis). the aetiologic factors are unknown, but common airborne allergens and contact lenses have been implicated. lodoxamide trometamol may be effective against other ocular diseases where type-i, ige-mediated hypersensitivity (or mast cells) play a major role in the inflammatory process. prophylactic use of lomide eye drops will assist in minimising the allergic symptoms associated with seasonal allergic conjunctivitis.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

leo pharma limited - diflucortolone valerate 0.1% - topical cream - 0.1 % - active: diflucortolone valerate 0.1% excipient: carbomer disodium edetate dihydrate liquid paraffin macrogol stearate 2000 methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium hydroxide stearyl alcohol white soft paraffin - all skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

alcon laboratories australia pty ltd (nz) - boric acid 0.2%{relative}; disodium edetate dihydrate 0.1%{relative}; hyetellose 0.8%{relative}; sodium chloride 0.6%{relative} - contact lens solution - active: boric acid 0.2%{relative} disodium edetate dihydrate 0.1%{relative} hyetellose 0.8%{relative} sodium chloride 0.6%{relative} excipient: borax hydrochloric acid policapram polidronium chloride polysorbate 21 purified water sodium hydroxide

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

morgan and hall ltd - dibasic sodium phosphate 0.33%; disodium edetate dihydrate 0.02%; sodium acetate trihydrate 0.827%; sodium chloride 0.018% - contact lens solution - active: dibasic sodium phosphate 0.33% disodium edetate dihydrate 0.02% sodium acetate trihydrate 0.827% sodium chloride 0.018%

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - piperacillin monohydrate 2 g (as piperacillin sodium 2.085g);  ;  ; tazobactam 250mg; piperacillin monohydrate 2 g (as piperacillin sodium 2.085g); tazobactam 250mg (as tazobactam sodium 0.2683 g) - powder for injection - 2g/250mg - active: piperacillin monohydrate 2 g (as piperacillin sodium 2.085g)     tazobactam 250mg piperacillin monohydrate 2 g (as piperacillin sodium 2.085g) tazobactam 250mg (as tazobactam sodium 0.2683 g) excipient: citric acid monohydrate disodium edetate dihydrate sodium bicarbonate - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of tazocin ef plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: tazocin ef is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, tazocin ef is indicated for the treatment of serious intra-abdominal infections.